Understand the Total Market Size and Treatment Opportunities for Biomarkers
The development of biomarker-driven therapies continues to be a major trend in oncology. Because biomarkers are often clinically relevant in more than one indication, the concept of sizing eligible patient populations is evolving. With DRG Biomarker Epidemiology data and insights, the entire biomarker-defined population can be sized in minutes.
DRG Epidemiology's coverage of ALK-mutated tumors comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the incidence of ALK-mutated tumors for each country, as well as annualized case counts projected to the national population.
In addition to forecasting incident patient populations, the number of drug-treatment opportunities at specific lines of therapy are also forecast across the major mature pharmaceutical markets.
DRG Epidemiology's ALK-mutated tumors forecast will answer the following questions:
- How will decreasing recurrence risk change the number of first-line drug-treatment opportunities for ALK-mutated tumors?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of ALK-mutated tumors over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient-flow diagrams are provided at the regional level, but may be requested for any specific country or forecast year.
In addition to the total number of cases for each forecast year, DRG Epidemiology also provides at least ten years of forecast data for the following ALK-mutated tumors subpopulations:
- Incident cases of ALK-mutated tumors by primary tumor site.
- Incident cases of ALK-mutated tumors by metastatic status.
- First-line drug-treatable population of ALK-mutated tumors, split by site of primary tumor.
Note: Coverage may vary by country.
You need biomarker epidemiology data you can trust in order to:
- Complete biomarker-driven market-sizing assessments based on patient population sizes and patient flows.
- Build the foundation of a market forecast for strategic planning for biomarker-targeting for new and existing assets.
- Understand how the patient populations for certain biomarkers will evolve over time.
- Answer any question you may have about specific subpopulations, biomarkers, and the impact of new studies.
- ALK - Epidemiology - Mature Markets Data
- Key Findings
- Diagnosed Incidence of ALK-Mutated Cancers per 100,000 People of All Ages in 2018 and 2028
- Analysis of the Diagnosed Incidence of ALK-Mutated Cancers in 2018 by Cancer Site
- Patient Flow Diagram for ALK-Mutated Cancers in 2018
- Epidemiology Data
- Diagnosed Incident Cases
- Diagnosed Breast Cancer Incident Cases
- Diagnosed Colorectal Cancer Incident Cases
- Diagnosed NSCLC Incident Cases
- Diagnosed Renal Cell Carcinoma Incident Cases
- Diagnosed Thyroid Carcinoma Incident Cases
- Diagnosed First-Line Drug-Treatable Population
- Diagnosed First-Line Breast Cancer Drug-Treatable Population
- Diagnosed First-Line Colorectal Cancer Drug-Treatable Population
- Diagnosed First-Line NSCLC Drug-Treatable Population
- Diagnosed First-Line Renal Cell Carcinoma Drug-Treatable Population
- Diagnosed First-Line Thyroid Carcinoma Drug-Treatable Population
- Reference Materials
- Literature Review
- Studies Included in the Analysis of the Prevalence of ALK-Mutated Breast, Colorectal, NSCLC, Renal Cell, or Thyroid Cancers
- Studies Excluded in the Analysis of the Prevalence of ALK-Mutated Breast, Colorectal, NSCLC, Renal Cell, or Thyroid Cancers
- Risk/Protective Factors
- Literature Review
Author(s): Alison Isherwood, MSc, MRes, PhD
Alison Isherwood, B.Sc., M.Res., M.Sc., Ph.D. joined Decision Resources Group in 2008, as an Epidemiologist. Alison holds a B.Sc. in Medical Microbiology, Masters by Research in the Life Sciences and a M.Sc. in Epidemiology all from the University of Edinburgh. Prior to joining Decision Resources Inc., she was working on her Ph.D. in Molecular Virology, specializing on the severe acute respiratory syndrome (SARS) coronavirus, at the University of Reading. In her role at Decision Resources Group, Alison is currently an Epidemiology team lead as well as project managing custom epidemiology work in multiple therapy areas. Alison’s area of specialization at DRG is cancer, particularly breast cancer.